Rudolph M Navari, Rui Qin, Kathryn J Ruddy, Heshan Liu, Steven F Powell, Madhuri Bajaj, Leah Dietrich, David Biggs, Jacqueline M Lafky, Charles L Loprinzi
BACKGROUND: We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy. METHODS: In a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patients with no previous chemotherapy who were receiving cisplatin (≥70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin...
July 14, 2016: New England Journal of Medicine